Article By:
Lipper Alpha Insight
Thursday, September 30, 2021 5:37 AM EDT
Merck is in some ways a victim of its own success. Its cancer treatment, Keytruda, represents a growing percentage and already over a third of revenue at the $185 billion pharmaceutical company.
